NCT06081920招募中2 期
A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI363 in Subjects With Advanced Melanoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 180
- 试验地点
- 17
- 主要终点
- PFS (progression free survival)
研究概览
简要总结
This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically and/or cytologically confirmed, unresectable, locally advanced or metastatic melanoma (according to the American Joint Committee on Cancer (AJCC) 8th edition staging III-IV). Progression or recurrence after at least first-line systemic standard treatment.
- •At least one measurable lesion (target lesion) per RECIST v1.
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or
- •Life expectancy of 3 months or more.
- •Female subjects of childbearing age or male subjects whose partners are female subjects of childbearing age agree to strictly adopt effective contraceptive measures throughout the entire treatment period and 6 months after the treatment period.
排除标准
- •Pregnant or lactating subjects, or subjects who plan to conceive before, during, or within 6 months after the last dose of the study drug.
- •Active or symptomatic central nervous system metastasis.
- •At baseline (within 7 days before the first administration of the study drug), there were any hematological abnormalities as follows: hemoglobin<90 g/L; Absolute neutrophil count (ANC)<1.5 × 109/L; Platelet count<100 × 109/L.
- •At baseline (within 7 days prior to first administration), there were any serum biochemical abnormalities as follows: Total bilirubin>1.5 × ULN; AST or ALT>3 × ULN; If it is tumor liver metastasis, AST or ALT>5.0 × ULN; Serum creatinine>1.5 × ULN or CCr<45 mL/min, using the Cockcroft Fault formula to calculate CCr (using actual body weight); Albumin<30 g/L.
- •At baseline (within 7 days before first administration), there were any coagulation parameter abnormalities as follows: INR>1.5 × ULN (>3 if receiving anticoagulant therapy with stabilizer dosage) × ULN); PTT (or activated partial thromboplastin time (aPTT))>1.5 × ULN (>3 if receiving anticoagulant therapy with stabilizer dosage) × ULN).
- •History of active thrombosis, deep vein thrombosis, or pulmonary embolism within 4 weeks prior to the first administration of the investigational drug, unless sufficient treatment has been given and the investigator believes that the condition is stable.
- •Uncontrolled bleeding or known tendency to bleed.
研究组 & 干预措施
IBI363
Experimental
干预措施: IBI363 (Biological)
结局指标
主要结局
PFS (progression free survival)
时间窗: 2 years
DCR (disease control rate)
时间窗: 2 years
TTR (time to response)
时间窗: 2 years
DoR（duration of response）
时间窗: 2 years
AE（Adverse event）
时间窗: 2 years
ORR（Objective response rate）
时间窗: 2 years
TTP (time to progression)
时间窗: 2 years
次要结局
- OS（overall survival）(2 years)
- PK concentration: IBI363 serum concentration(2 years)
- ADA (Anti-drug antibody)(2 years)
- Nab (Neutralizing antibody)(2 years)
研究者
研究点 (17)
Loading locations...
相似试验
已完成
2 期
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)Marginal Zone LymphomaDiffuse Large B-Cell LymphomaFollicular LymphomaNCT03520920BeiGene41
已完成
2 期
Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid TumorsHER2-positive Solid TumorsNCT04521179Jiangsu Alphamab Biopharmaceuticals Co., Ltd102
终止
2 期
SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid TumorsHER2-expressing or -Mutated Unresectable or Metastatic Solid TumorsNCT06516926Jiangsu HengRui Medicine Co., Ltd.11
终止
2 期
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract CancerBiliary Tract CancerNCT05998447Genome & Company10
Unknown
1 期
A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C MutationAdvanced Solid TumorNCT05119933Shanghai YingLi Pharmaceutical Co. Ltd.55